HemaSphere (Aug 2023)
PB1808: EPIGENETIC INHIBITOR SCREEN TO IDENTIFY THERAPEUTIC CANDIDATES FOR MNX1-OVEREXPRESSING AML
- Simge Kelekci,
- Anna Riedel,
- Dieter Weichenhan,
- Ashish Goyal,
- Katherine Kelly,
- Marion Baehr,
- Birgitta Michels,
- Cindy Koerner,
- Irene Orzella,
- James Dunford,
- Pavlo Lutsik,
- Stefan Wiemann,
- Udo Oppermann,
- Christoph Plass
Affiliations
- Simge Kelekci
- 1 German Cancer Research Center, Division of Cancer Epigenomics, Heidelberg, Germany
- Anna Riedel
- 1 German Cancer Research Center, Division of Cancer Epigenomics, Heidelberg, Germany
- Dieter Weichenhan
- 1 German Cancer Research Center, Division of Cancer Epigenomics, Heidelberg, Germany
- Ashish Goyal
- 1 German Cancer Research Center, Division of Cancer Epigenomics, Heidelberg, Germany
- Katherine Kelly
- 1 German Cancer Research Center, Division of Cancer Epigenomics, Heidelberg, Germany
- Marion Baehr
- 1 German Cancer Research Center, Division of Cancer Epigenomics, Heidelberg, Germany
- Birgitta Michels
- 3 German Cancer Research Center, Division of Molecular Genome Analysis, Heidelberg, Germany
- Cindy Koerner
- 3 German Cancer Research Center, Division of Molecular Genome Analysis, Heidelberg, Germany
- Irene Orzella
- 4 Universita degli studi di Camerino, Department of Pharmacy, Camerino, Italy
- James Dunford
- 5 University of Oxford, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom
- Pavlo Lutsik
- 1 German Cancer Research Center, Division of Cancer Epigenomics, Heidelberg, Germany
- Stefan Wiemann
- 3 German Cancer Research Center, Division of Molecular Genome Analysis, Heidelberg, Germany
- Udo Oppermann
- 5 University of Oxford, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom
- Christoph Plass
- 1 German Cancer Research Center, Division of Cancer Epigenomics, Heidelberg, Germany
- DOI
- https://doi.org/10.1097/01.HS9.0000974080.68856.1e
- Journal volume & issue
-
Vol. 7
p. e688561e
Abstract
No abstracts available.